Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-41521
Dummer, R; Eichmüller, S; Gellrich, S; Assaf, C; Dreno, B; Schiller, M; Dereure, O; Baudard, M; Bagot, M; Khammari, A; Bleuzen, P; Bataille, V; Derbij, A; Wiedemann, N; Waterboer, T; Lusky, M; Acres, B; Urosevic-Maiwald, M (2010). Phase II clinical trial of intratumoral application of TG1042 (adenovirus-interferon-gamma) in patients with advanced cutaneous T-cell lymphomas and multilesional cutaneous B-cell lymphomas. Molecular Therapy, 18(6):1244-1247.
- Registered users only
View at publisher
Cutaneous lymphomas (CLs) are a heterogeneous group of lymphoproliferative disorders that are manageable by immunotherapy. Twenty-one patients were enrolled in a prospective open-label, dose-escalation multicenter study evaluating the effects of repeated TG1042 [adenovirus-interferon (IFN)-gamma] intralesional injections in patients with primary CLs, of which 18 were of T-cell and 3 of B-cell type. Repeated intralesional therapy using TG1042 consistently results in local tumor regressions in about half of treated patients and one-third of patients also in regressions in noninjected distant lesions, likely reflecting the systemic immune activation after intralesional therapy. Treatment was well tolerated with few adverse events including injection site reactions, chills, lymphopenia, and fever. Immune monitoring in the peripheral blood demonstrated systemic immune activation and the induction of antibodies against tumor antigens in some patients without clear association with clinical responses. CLs, in particular B-cell lymphomas with high objective response rates, seem to be excellent targets for this type of immunotherapy.
1 download since deposited on 08 Jan 2011
0 downloads since 12 months
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Dermatology Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||08 Jan 2011 17:41|
|Last Modified:||28 Nov 2013 00:13|
|Publisher:||Nature Publishing Group|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page